Structure TherapeuticsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Q3 2022-Q2 2026(All available data)
Q4 2021-Q2 2026(All available data)
Structure TherapeuticsClinical-stage biotech. Lead asset aleniglipron: oral small-molecule GLP-1 agonist. Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted weight loss at 36 weeks. Roche licensing deal ($100M) for additional assets.
Structure Therapeutics (GPCR) is a Biotechnology company. Clinical-stage biotech. Lead asset aleniglipron: oral small-molecule GLP-1 agonist. Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted weight loss at 36 weeks. Roche licensing deal ($100M) for additional assets. It was founded in 2018, is headquartered in South San Francisco, CA and employs about 80 people.
Track Structure Therapeutics's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 21, 2026.
Sterling groups Structure Therapeutics in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Structure Therapeutics, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.